Hodjattallah Rabbani

Title: The Innovative Contributions of Hodjattallah Rabbani

Introduction

Hodjattallah Rabbani is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic and diagnostic methods for cancer.

Latest Patents

Hodjattallah Rabbani holds 2 patents that focus on innovative approaches to cancer treatment. His latest patents include "Biological inhibitors of ROR1 capable of inducing cell death," which relates to antibodies and siRNA molecules designed to induce cell death through the specific binding of ROR1. This invention also provides methods and uses for these antibodies and siRNA molecules. Another significant patent is titled "Diagnostic and therapeutic target," which describes an in vitro method for assessing cancer risk by measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells. An increased expression level of PRELP indicates a higher probability of cancer in the subject. This patent also includes antibodies specific for PRELP and their applications in diagnosis and therapy.

Career Highlights

Throughout his career, Hodjattallah Rabbani has worked with various organizations, including Kancera AB and Avicenna Research Institute. His work has focused on advancing cancer research and developing innovative solutions for diagnosis and treatment.

Collaborations

Hodjattallah has collaborated with several professionals in his field, including Ingrid Teige, to further enhance his research and development efforts.

Conclusion

Hodjattallah Rabbani's contributions to cancer research through his patents and collaborations highlight his commitment to innovation in biotechnology. His work continues to pave the way for new diagnostic and therapeutic methods that can significantly impact patient care.